Shares of Exelixis, Inc. (EXEL) have surged 25% in a month against the industry’s decline of 4.9%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The outperformance can be attributed to better-than-expected third-quarter results. The company also raised its annual guidance.Exelixis has been a consistent outperformer of late on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.EXEL Outperforms Industry, Sector & S&P 500Image So ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Z ...

It is not surprising that before any earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap stocks that are of high quality.In this regard, we ran a screener that yielded stocks Amazon.com (AMZN) , Maplebear Inc. (CART) , Exelixis (EXEL) and Doximity (DOCS) as the likely winners on the earnings beat potential.Why Is a Positive Earnings Surprise So Important?Historically, stocks of companies ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the trad ...

Exelixis (EXEL) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The upward trend in estimate revisions for this drug developer reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends ...

Since my January 2024 article, Exelixis, Inc. (NASDAQ: EXEL ) has appreciated significantly. I believe this has been mostly due to Cabometyx’s continued success and its pipeline’s strategic progress. EXEL aims to become a genitourinary [GU] and gastrointestinal [GI] oncology leader. Its leading product is Cabometyx, aMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer scie ...

Exelixis, Inc. (EXEL) reported better-than-expected third-quarter results. Its shares have risen following the announcement.EXEL recorded earnings of 47 cents per share, which beat the Zacks Consensus Estimate of 42 cents. The company registered adjusted earnings of 10 cents per share in the third quarter of 2023. The upside was mainly driven by higher revenues and lower operating expenses.Including stock-based compensation expense, earnings were 40 cents per share in the reported quarter.Stay up-to-date wi ...

TUESDAY, OCTOBER 29, 2024 Third Quarter 2024 Financial Results Nasdaq: EXEL EXELIXIS® Today's Agenda Introduction Varant Shirvanian Director, Investor Relations Business Update and Q3 2024 Highlights Michael M. Morrissey, Ph.D. President and CEO Financial Results & Guidance Chris Senner EVP and CFO Commercial Update PJ Haley EVP, Commercial Q&A All, joined by: Amy Peterson, M.D. EVP, Product Development and Medical Affairs and CMO Dana T. Aftab, Ph.D. EVP, Discovery and Translational Research and CSO 2 Safe ...